Cytek Biosciences (CTKB) Payables (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Payables data on file, last reported at $6.7 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 7.91% year-over-year to $6.7 million; the trailing twelve-month figure through Mar 2026 stood at $6.7 million (up 7.91% YoY), and the FY2025 full-year result was $6.4 million, up 15.93% from the prior year.
• Payables for Q1 2026 stood at $6.7 million, up from $6.4 million in the prior quarter.
• Across five years, Payables topped out at $7.6 million in Q3 2025 and bottomed at $3.0 million in Q4 2023.
• The 5-year median for Payables is $5.5 million (2024), against an average of $5.4 million.
• The widest annual swing landed in 2023, when Payables sank 54.33%; it then soared 114.76% in 2025.
• A 5-year view of Payables shows it stood at $4.8 million in 2022, then slumped by 36.9% to $3.0 million in 2023, then soared by 82.35% to $5.5 million in 2024, then increased by 15.93% to $6.4 million in 2025, then grew by 5.16% to $6.7 million in 2026.
• The last three Payables figures came in at $6.7 million (Q1 2026), $6.4 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.

Peer Comparison